A blood test for colon cancer performed well in a study published Wednesday, offering a new kind of screening for a leading cause of cancer deaths.
The test looks for DNA fragments shed by tumor cells and precancerous growths. It’s already for sale in the U.S. for $895, but has not been approved by the Food and Drug Administration and most insurers do not cover it. The maker of the test, Guardant Health, anticipates an FDA decision this year.
In the study, the test caught 83% of the cancers but very few of the precancerous growths found by colonoscopy, the gold standard for colon cancer screening. Besides spotting tumors, colonoscopies can prevent the disease by removing precancerous growths called polyps.
But some people avoid the exam because of the hassle of getting time off work or the day-ahead preparation that involves drinking a strong laxative to empty the bowels.
Related articles:
Related suggestion:
Xi Holds Talks with Sierra Leonean PresidentChina's top diplomat to attend Munich Security Conference, visit Spain and FranceFive factors to affect RussiaMacao's electoral affairs commission for chief executive election takes officeChina's top diplomat to attend Munich Security Conference, visit Spain and FrancePresident Xi Jinping's Letter Presented to American StudentsSound relations built on 70 years of friendshipUganda says antiDomestic tourism industry set for 'full recovery' by summerXi Focus: Xi's Thought on Ecological Civilization Guides Xiamen's Green Shift
1.5482s , 6496.2578125 kb
Copyright © 2024 Powered by Colon cancer blood test offers new screening option ,World Wave news portal